Bibliographic Details
| Title: |
Clinical Impact of Proton Beam Therapy for Postoperative Lymph Node Oligorecurrence of Esophageal Cancer. |
| Authors: |
YUICHI HIROSHIMA, HITOSHI ISHIKAWA, TAISUKE SUMIYA, MOTOHIRO MURAKAMI, MASATOSHI NAKAMURA, TOSHIKI ISHIDA, KOICHI OGAWA, KATSUJI HISAKURA, MASASHI MIZUMOTO, TATSUYA ODA, TOSHIYUKI OKUMURA, HIDEYUKI SAKURAI |
| Source: |
In Vivo; May/Jun2023, Vol. 37 Issue 3, p1253-1259, 7p |
| Subject Terms: |
PROTON therapy, LYMPH nodes, ESOPHAGEAL cancer, HEALTH outcome assessment, RADIOTHERAPY |
| Abstract: |
Background/Aim: Radiotherapy is a salvage therapy type for postoperative recurrence of esophageal cancer. Compared to conventional photon-based radiotherapy, proton beam therapy can reduce the irradiated dose to the surrounding organs, facilitating the management of patients who are unfit for radiotherapy. In this study, the outcomes and toxicity of proton beam therapy for postoperative lymph node oligorecurrence of esophageal cancer were investigated. Patients and Methods: We retrospectively evaluated the clinical outcomes and toxicity of 13 sites in 11 patients treated with proton beam therapy for postoperative lymph node oligorecurrence of esophageal cancer. In total, eight men and three women with a median age of 68 years (range=46-83 years) were included. Results: The median follow-up period was 20.2 months. During the follow-up period, four patients died of esophageal cancer. Eight of the 11 patients developed recurrence; of these, seven patients had recurrence outside the irradiated field, and one had recurrence inside and outside the irradiated field. The 2-year overall survival, progression-free survival, and local control rates were 48.0%, 27.3%, and 84.6%, respectively. The median survival time was 22.4 months. There were no severe acute or late adverse events. Conclusion: Proton beam therapy could be a safe and effective treatment method for postoperative lymph node oligorecurrence of esophageal cancer. It may be beneficial even in cases where conventional photon-based radiotherapy is difficult to administer in combination with increased doses or with chemotherapy. [ABSTRACT FROM AUTHOR] |
|
Copyright of In Vivo is the property of International Institute of Anticancer Research and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Complementary Index |
